ArticleInternational urology and nephrology2026
Comparing benign to malignant cystectomy: complications, emergency department utilization, readmissions, and socioeconomic status.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Urinary tract infections after benign cystectomy: Incidence, risk factors, pathogens, and resistance patterns.Investigative and clinical urology · 2026Article
- The Effect of the Area Deprivation Index on Surgical Outcomes for Benign Cystectomy.Advances in urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionResearch has often focused on radical cystectomy for bladder cancer; however, there is an entirely different population, namely those who undergo cystectomy for benign, non-cancerous reasons, which requires attention. The purpose of this study was to compare patients who underwent cystectomy for benign (BC) and malignant (MC) reasons, focusing on complications, emergency department (ED) utilization, readmission, and socioeconomic status (SES).
methodsCystectomies performed at our institution from 2012 to 2025 were reviewed. Patients were divided based on indication into BC versus MC (for bladder cancer with pathologic confirmation). Non-oncologic cystectomies were either for neurogenic bladder, interstitial cystitis/bladder pain syndrome, or "other reasons." Complications were divided into in-house immediately following cystectomy prior to discharge and those occurring within 90 days of discharge. The Memorial Sloan Kettering Cancer Center classification system of cystectomy complications was used to qualify complications. ED utilization and readmissions were charted within the first 90 days of discharge. Area Deprivation Index (ADI) scores, which assign rankings to SES for neighborhoods, were used as a surrogate for patient SES. BC and MC patients were compared.
results569 patients were included in the analysis (183 BC and 386 MC). Urinary diversion choice differed between groups, with more cutaneous ureterostomies in MC patients and Indiana Pouches in BC patients (p < 0.001). In-house complications were significantly greater in the benign cohort (51%) compared with the malignant cohort (36%; p < 0.001). ED utilization within 90 days of discharge was greater in BC (51%) relative to MC (34%; p < 0.001) patients, and BC patients were more likely to visit the ED with no readmission (p < 0.001). 69 (40%) patients were readmitted in the BC group, and 67 (17%; p < 0.001) patients were readmitted in the MC group. ADI scores 1-4 (higher SES) were more common in BC patients (p = 0.012).
conclusionsBC patients have greater rates of healthcare utilization compared to those undergoing MC. While recognizing these patient populations are not the same, the causes of these differences call for additional investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.